← Leaderboards
Joanne L Billings
University Of Minnesota Twin Cities
$975,613
Attributed
$975,613
Total exposure
12
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $185.2K · FY2005–09$200K$150K$100K$50K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$975,613 · 12
By mechanism
K23$708,450 · 1
M01$267,163 · 11
Top collaborators
No co-investigators on record.
Most similar at University Of Minnesota Twin Cities
Same institution · by research overlap
- Pierre-Gilles Henry$2,759,493
- Wei Chen$27,041,799
- Peter B Bitterman$13,879,552
- Rolf Gruetter$3,406,414
- David A Bernlohr$13,927,503
Others in their field
Top investigators on “Cystic Fibrosis”
- John F Engelhardt · University Of Iowa$42,933,706
- Michael R Knowles · University Of North Carolina Chapel Hill$30,250,682
- David A Stoltz · University Of Iowa$25,455,359
- Joseph Zabner · University Of Iowa$25,382,103
- Paul B McCray · University Of Iowa$25,146,293
- Richard C Boucher · University Of North Carolina Chapel Hill$24,890,955
Research focus
Cystic FibrosisComputer Retrieval Of Information On Scientific Projects DatabaseResearch PersonnelEstrogensProgesteroneUnited States National Institutes Of HealthHormone Regulation /Control MechanismInstitutionResourcesSourceGrantFundingOral ContraceptivesWomen'S HealthPatient Oriented ResearchHuman SubjectRespiratory FunctionFemaleMenstrual CycleClinical ResearchSafetyBreathingSputumPseudomonas Aeruginosa
Grant awards (16)
MULTIDOSE SAFETY AND TOLERABILITY STUDY OF LIPOSOMAL AMIKACIN FOR INHALATION (AR$20,125
M01 · FY2009 · RR · contact PI
KB001-03: A PHASE I/II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-DOSE$6,952
M01 · FY2009 · RR · contact PI
EXPANDED ACCESS PROGRAM FOR AZTREONAMN LYSINE FOR INHALATION IN PATIENTS WITH CY$5,854
M01 · FY2009 · RR · contact PI
A PHASE 3, DOUBLE-BLIND, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH$34,453
M01 · FY2008 · RR · contact PI
INHALED SODIUM PYRUVATE FOR THE TREATMENT OF CYSTIC FIBROSIS A PHASE I, DOUBLE$3,092
M01 · FY2008 · RR · contact PI
WOMEN'S HEALTH IN CYSTIC FIBROSIS$7,855
M01 · FY2007 · RR · contact PI
WOMEN'S HEALTH IN CYSTIC FIBROSIS$68,508
M01 · FY2006 · RR · contact PI
A PHASE II, RANDOMIZED, DOUBLE BLIND, PARALLEL DOSE STUDY OF ORAL THERACLEC-TOTA$44,476
M01 · FY2006 · RR · contact PI
WOMEN'S HEALTH IN CYSTIC FIBROSIS$124,846
K23 · FY2005 · HL
WOMEN'S HEALTH IN CYSTIC FIBROSIS$47,246
M01 · FY2005 · RR
A PHASE II, RANDOMIZED, DOUBLE BLIND, PARALLEL DOSE STUDY OF ORAL THERACLEC-TOTA$13,077
M01 · FY2005 · RR
WOMEN'S HEALTH IN CYSTIC FIBROSIS$137,152
K23 · FY2004 · HL
Women's Health in Cystic Fibrosis$15,525
M01 · FY2004 · RR
WOMEN'S HEALTH IN CYSTIC FIBROSIS$160,272
K23 · FY2003 · HL
WOMEN'S HEALTH IN CYSTIC FIBROSIS$159,939
K23 · FY2002 · HL
WOMEN'S HEALTH IN CYSTIC FIBROSIS$126,241
K23 · FY2001 · HL